Packaging Supervisor

HLN stock slides as momentum breaks key support. TIM BOHEN - UPDATED OCT. 29, 2026, 12:34 PM ET Summarize this article Haleon plc faces heightened investor concern over product litigation risks, with stocks having been trading down by -14.55 percent. Key takeaways. * Price action in HLN shows a sharp break from the $10 range down toward the mid-$8s, signaling a change in short-term momentum. * Intraday HLN trading has shifted into a tight consolidation band around $8.50, suggesting traders are debating the next leg. * Profit margins at Haleon plc remain strong, but revenue growth is flat to slightly negative over three years. * HLN carries moderate leverage with a low current ratio, so balance-sheet strength is solid but not bulletproof. * Active traders are watching prior support near $8.80-$9.00 on HLN as a key area for potential bounces or further breakdowns. Live Update At 12:33:59 EDT: On Thursday, October 29, 2026 Haleon plc stock [NYSE: HLN] is trending down by -14.55%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. HLN, the consumer-health spinout now trading on its own, is a classic "steady business, choppy stock" setup. Haleon plc posts about $11.03B in annual revenue with a healthy gross margin near 65%. That means HLN keeps roughly two-thirds of every sales dollar after basic product costs, a strong base for a defensive name. On the bottom line, HLN runs an EBIT margin of 22% and profit margin around 14-15%. Those are solid numbers, not hyper-growth tech, but the kind of dependable earnings traders often lean on in volatile markets. The trade-off is growth: revenue over the last three years is slightly negative, so the HLN story is more about efficiency and brand power than rapid expansion. Valuation is middle of the road. A P/E around 19.4 and price-to-sales near 2.75 put HLN in "reasonably priced quality" territory, not a deep value bargain but not a bubble either. Debt metrics matter here. Total debt to equity at 0.5 and interest coverage at 8.8 show Haleon plc can handle its obligations, though a current ratio of 0.7 keeps pressure on cash management. For traders, HLN looks like a stable earnings machine currently dealing with unstable price action. Why traders are watching HLN price support. The real story for active traders is the chart. HLN spent much of the recent daily action grinding higher from the high-$8s to the low-$10s. Then the floor gave out. After closing at $10.00, Haleon plc dropped hard into the mid-$8s, finishing the latest session around $8.545. That's more than a 14% slide from recent highs near $10.37, a clear signal that momentum bulls lost control. On the multi-day chart, HLN had been respecting the $9.50-$10.30 band, with a slow, steady uptrend. When a defensive consumer-health name like Haleon plc suddenly cracks that range, experienced traders pay attention. That kind of move often means bigger funds rotated out, or that expectations simply got ahead of reality. Zoom into the intraday 5-minute data and HLN shows a classic "gap-down, grind-sideways" pattern. Pre-market prints ran near $8.80-$8.90. The regular-session open around $8.55 saw an early push to $8.75, then a steady bleed down toward the low-$8.40s before a mild midday bounce to the $8.50s. Range tightened quickly, with HLN oscillating roughly between $8.40 and $8.60 for hours. That compression tells traders the panic phase passed, at least for now, and Haleon plc has slipped into decision mode. Either HLN holds this $8.40-$8.60 area and builds a base, or it loses that line and heads toward prior support from early in the run. For short-term players, the key levels are simple. On the upside, reclaiming $8.90-$9.00 would show HLN regaining lost ground and possibly turning the breakdown into a shakeout. On the downside, a decisive break under $8.40 with volume would likely invite more selling as stops trigger. With HLN's solid but not blazing fundamentals, this is the kind of tape where chart discipline matters more than storytelling. Conclusion. HLN sits at an interesting crossroads where strong fundamentals meet weak price action. Haleon plc runs a profitable, wide-margin consumer-health operation with a 22% EBIT margin, respectable returns on equity, and a reasonable P/E for the sector. At the same time, revenue growth is soft, leverage is manageable but present, and the current ratio under 1 means Haleon plc cannot relax on liquidity. Traders in HLN need to respect that contrast. The long-term story is steady brands and cash flow. The short-term story is a broken $10 level, heavy selling pressure, and a new battle line around the mid-$8s. Until HLN either reclaims lost resistance or knifes through support, this is a textbook wait-for-the-chart setup, not a "close your eyes and hope" situation. As Tim Bohen, lead trainer with StocksToTrade says, "A good trade setup checks all the boxes - volume, trend, catalyst. Don't trade if you're missing pieces of the puzzle." In the case of HLN, that means patiently waiting until the chart, liquidity, and catalysts all align instead of forcing trades based only on the fundamental story. For newer traders tracking HLN, this is where discipline separates pros from gamblers. As Tim Sykes loves to say, "The market doesn't care about your opinion, it cares about price action - so trade the chart, not the story." Haleon plc gives you the quality backdrop; HLN's chart tells you when the timing actually makes sense. This content is for educational and research purposes only and should not be taken as investment advice. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. The hours when the stock market is closed to everyone except you. Every week, there's a stretch of time when the biggest players on Wall Street physically leave the market and don't come back until Monday. Meanwhile, news keeps breaking on hundreds of small, overlooked companies. Millionaire trader Tim Sykes calls that window the Weekend Gap, and it's the reason he can buy a small stock on a Friday afternoon, close his laptop, and check back Monday morning to see what happened while the market was shut. He recorded a free video walking through exactly how it works.

Haleon shares crater as soft flu demand hits takings. Retail Reporter Shares in Haleon slumped after soft demand for cough, cold and flu medicines forced the consumer healthcare giant to cut its revenue target. The FTSE 100 firm lost more than 11 per cent in early trading, to 333p. Haleon had been expecting revenue growth of between three and five per cent but on Thursday trimmed this target to 2.5 per cent. The Surrey-based group has warned repeatedly this year that soft cold and flu seasons are hitting sales, and its share price has shed more than 10 per cent in the year to date. Lower demand for flu medicines slowed Haleon's sales growth in North America from 3.1 to 2.5 per cent, though higher demand for toothpaste brand Sensodyne was a bright spot in this market. Haleon, which split off from pharmaceuticals giant GSK in 2022, saw revenue dip by 0.6 per cent in Europe, owing to weak sales of Centrum, its multivitamin supplement brand, which it blamed on "weaker category trends". Stay in the know Three daily briefings with the key market moves and top business and political stories. The group was forced to suspend shipments of Centrum into China after a change in raw material regulations affected imports of the over-the-counter vitamins. Despite this, sales in China grew by mid-single digits. Haleon said it saw only low-single digit growth in south-east Asia and Taiwan, because of the "softer consumer backdrop" caused by the conflict in the Middle East. Consumer health firms under pressure. Chief executive Brian McNamara said: "Our third quarter organic revenue growth of 2.6 per cent was below our expectations as we navigated softness across some of our categories including weaker cough, cold and flu consumption. "We are clear on where we need to improve and we are taking action to deliver stronger performance despite challenging markets." James Edwardes Jones, an analyst at stock broker RBC, said Haleon's third-quarter results "weren't great" but its cut to revenue guidance was "worse". "True, profit guidance has been maintained, but following Reckitt's results a couple of days ago, consumer health companies have claimed a notably unenviable position amongst the stocks we cover," he said. Earlier this week Dettol and Durex owner Reckitt, Haleon's FTSE 100 rival, lowered its profit guidance after production issues hit production of Lysol, its disinfectant brand, in the US. Shares in Reckitt have lost more than 15 per cent in the year to date, though they gained more than one per cent in early trading on Thursday.

Haleon shares dive after Advil maker cuts guidance - 2nd update. Published on 10/29/2026 at 04:52 am EDT By Aimee Look Advil maker Haleon's shares dove after the company cut its outlook for the year and weak sales for cough medications weighed on results. The company, which spun out of pharmaceutical group GSK in 2022, said it now expects full-year organic revenue growth around 2.5%. Haleon at its half-year results in July said it expected organic revenue growth of 3% to 5%. Shares dropped 13.5% in early morning trading in Europe. The British consumer-healthcare company's performance was held back by weaker sales in cough, cold and flu products, particularly with lower orders in North America, it said. Its respiratory-health category had a 2% fall in organic revenue. Other consumer-goods companies across various categories, like British Lysol-maker Reckitt and French yogurt producer Danone, were also held back by a lack of progress in North America. However, before earnings, J.P. Morgan's Celine Pannuti had said that a strong flu season could uplift sales for Haleon, with rising incidences in Europe and the U.S. "An uptick in scanner data in the U.S. and [Western] Europe has spearheaded hopes that Haleon should benefit from growth momentum in upcoming quarters," the analyst wrote. While its respiratory-health category's revenue dropped, Haleon's oral-health category grew 8.8% organically for the quarter. In the company's international geography segment, organic revenue grew 6.9% for the quarter. Haleon's third quarter was disappointing, mainly due to the weaker cold and flu results, said Barclays analyst Warren Ackerman. The company's results fell short in North America, and Europe remained challenged, he said. Oral health was a bright spot, he added. Haleon reported an overall 2.6% rise in organic revenue, booking 2.87 billion pounds, equivalent to $3.82 billion. Also on Thursday, Haleon said it is planning to purchase up to 500 million pounds of shares through a buyback, which it expects to complete by the full-year results in February 2027. Write to Aimee Look at [email protected] (END) Dow Jones Newswires 10-29-26 0451ET (C) Dow Jones - 2026